A detailed history of Summit Financial, LLC transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Summit Financial, LLC holds 1,379 shares of VRTX stock, worth $563,680. This represents 0.03% of its overall portfolio holdings.

Number of Shares
1,379
Previous 1,205 14.44%
Holding current value
$563,680
Previous $564,000 13.65%
% of portfolio
0.03%
Previous 0.03%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

BUY
$460.0 - $505.78 $80,040 - $88,005
174 Added 14.44%
1,379 $641,000
Q2 2024

Jul 31, 2024

BUY
$392.81 - $485.53 $260,433 - $321,906
663 Added 122.32%
1,205 $564,000
Q1 2024

Apr 24, 2024

SELL
$407.69 - $446.08 $127,199 - $139,176
-312 Reduced 36.53%
542 $226,000
Q4 2023

Feb 05, 2024

BUY
$343.0 - $410.68 $81,977 - $98,152
239 Added 38.86%
854 $347,000
Q3 2023

Nov 07, 2023

BUY
$338.18 - $362.46 $207,980 - $222,912
615 New
615 $213,000

Others Institutions Holding VRTX

About VERTEX PHARMACEUTICALS INC


  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $105B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track Summit Financial, LLC Portfolio

Follow Summit Financial, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Summit Financial, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Summit Financial, LLC with notifications on news.